Building
A Better
Tomorrow™
Tomorrow™
Our purpose is to build A Better Tomorrow™ by reducing the health impact of our business through offering a choice of less risky* products for our consumers. Science and innovation are accelerating our Tobacco Harm Reduction mission.
Focus
Our world-class scientists are generating evidence to support our New Category products. We are committed to making Tobacco Harm Reduction a reality.
We have published the results from our innovative cross-sectional clinical study of Velo, BAT’s flagship modern oral nicotine pouch product.
Research
We operate in a broad spectrum of scientific fields including molecular biology, toxicology and chemistry, and it is that breadth of expertise which fuels the relentless innovation and learning that sets us apart as an industry leader.
R&D Virtual Visitor Experience
Explore our global Research and Development hub
Publications
VapourNathan GaleMay 2022Biomarkers of Exposure and Potential Harm in Exclusive Users of Electronic Cigarettes and Current, Former and Never-Smokers: A Cross-Sectional Study Protocol- VapourAnnette DalrympleFebruary 2022Pilot study to determine differences in breath odour between cigarette and e-cigarette consumers
- VapourDavid SmartJanuary 2022Application of ToxTracker for the toxicological assessment of tobacco and nicotine delivery products
Insights
Director's ViewDr David O'Reilly shares his thoughts on science, COVID-19, and harm reduction
/
➜
➜
*Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
Our products as sold in the US, including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.